An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Journal:
Nature Medicine
Published:
DOI:
10.1038/s41591-021-01317-6
Affiliations:
22
Authors:
24
Institutions Authors Share
AstraZeneca plc, United Kingdom (UK)
7.000000
0.29
Centre Léon Bérard (CLB), France
1.500000
0.06
Queen Mary University of London (QMUL), United Kingdom (UK)
1.000000
0.04
CHU de Bordeaux, France
1.000000
0.04
University of Washington (UW), United States of America (USA)
1.000000
0.04
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
1.000000
0.04
Princess Margaret Cancer Centre, U of T, Canada
1.000000
0.04
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA)
1.000000
0.04
Cancer Research UK Manchester Institute, UoM, United Kingdom (UK)
1.000000
0.04
Institute of Cancer Research (ICO), France
1.000000
0.04
Yale University, United States of America (USA)
1.000000
0.04
Hospital de la Santa Creu i Sant Pau, Spain
1.000000
0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
0.04
Institut Paoli-Calmettes (IPC), France
1.000000
0.04
St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)
1.000000
0.04
The University of Manchester (UoM), United Kingdom (UK)
0.500000
0.02
UNICANCER Group, France
0.500000
0.02
University of Glasgow, United Kingdom (UK)
0.500000
0.02
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)
0.500000
0.02
The Christie NHS Foundation Trust, United Kingdom (UK)
0.500000
0.02